RALPH ABLASEAU: Open Payments
NPI 1982869715 · WILLIAMSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,111 in 109 payments from 16 companies in 2025. Trend: 2023 $1,175 · 2024 $4,524 · 2025 $2,111
Food & beverage: $1,996Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $428 |
| E.R. Squibb & Sons, L.L.C. | 9 | $249 |
| Otsuka America Pharmaceutical, Inc. | 12 | $206 |
| Supernus Pharmaceuticals, Inc. | 13 | $197 |
| Alkermes, Inc. | 9 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $180 |
| Vanda Pharmaceuticals Inc. | 9 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Janssen Pharmaceuticals, Inc | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $86 |
Products named: VRAYLAR, COBENFY, Qelbree, CAPLYTA, SPRAVATO, ARISTADA, FANAPT, REXULTI.
Industry payments across VA — which companies pay providers there.
